{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T06:11:03Z","timestamp":1759903863865,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/s0378-4274(23)00832-9","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:42:13Z","timestamp":1693957333000},"page":"S248-S249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S1","title":["P21-25: Targeting iron dysregulation and oxidative stress for the development of innovative therapeutics against neurodegeneration"],"prefix":"10.1016","volume":"384","author":[{"given":"R.","family":"Oliveira","sequence":"first","affiliation":[]},{"given":"A.R.","family":"Alfenim","sequence":"additional","affiliation":[]},{"given":"P.","family":"Soares","sequence":"additional","affiliation":[]},{"given":"F.","family":"Borges","sequence":"additional","affiliation":[]},{"given":"F.","family":"Remi\u00e3o","sequence":"additional","affiliation":[]},{"given":"C.","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"R.","family":"Silva","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"163","key":"10.1016\/S0378-4274(23)00832-9_bib1","first-page":"407","article-title":"Neurodegenerative diseases","author":"Checkoway","year":"2011","journal-title":"IARC scientific publications"},{"issue":"1","key":"10.1016\/S0378-4274(23)00832-9_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"European journal of neurology"},{"issue":"9996","key":"10.1016\/S0378-4274(23)00832-9_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"10360","key":"10.1016\/S0378-4274(23)00832-9_bib4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/S0378-4274(23)00832-9_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108373","article-title":"Molecular mechanisms of ferroptosis and their involvement in brain diseases","volume":"244","author":"Costa","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/S0378-4274(23)00832-9_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Scientific reports"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427423008329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427423008329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:29:45Z","timestamp":1759901385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427423008329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":6,"alternative-id":["S0378427423008329"],"URL":"https:\/\/doi.org\/10.1016\/s0378-4274(23)00832-9","relation":{},"ISSN":["0378-4274"],"issn-type":[{"type":"print","value":"0378-4274"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P21-25: Targeting iron dysregulation and oxidative stress for the development of innovative therapeutics against neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0378-4274(23)00832-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}